Table 1 Summary of study characteristics
From: Serum and blood based biomarkers for lung cancer screening: a systematic review
Jett et al. 2014 | Sozzi et al. 2014 | Montani et al. 2015 | |
|---|---|---|---|
Test Evaluated | EarlyCDT-lung | MSC | miR-test |
Number of patients | 1613 | 939 | 1008 |
Patient Inclusion Criteria | EarlyCDT-lung test made available to treating physicians Clear inclusion criteria not defined | MILD trial participants: > 20 pack-years smoking history > 50 years old without history of cancer in past 5 years. 1000 consecutive plasma samples from trial participants Additional 69 plasma samples from 85 patients with lung cancer in MILD trial | COSMOS trial participants: > 20 pack-years smoking > 50 years old Lung cancer patients diagnosed outside of COSMOS trial |
Patient Exclusion Criteria | Clear exclusion criteria not defined | Hemolyzed samples No known pulmonary pathology | No known pulmonary pathology |
Follow-up Period | 6 months | 5 years | Unknown |
Key Study limitations | Audit trial used in regular physician practice No clear eligibility criteria No clear lung cancer diagnostic criteria No baseline characteristics of population No distribution of alternative diagnosis in those without target condition No discussion of study limitations, biases, uncertainty No link to full study protocol No discussion of sources of funding | No discussion of how sample size was determined No distribution of alternative diagnosis for those without lung cancer | No indication of whether clinical information available to performers/readers of tests No discussion of how sample size was determined No distribution of alternative diagnosis in those not diagnosed with lung cancer Very brief discussion of study limitations |